Le Lézard
Subjects: Conference, Product/Service, Trade Show

Alcon #Academy21 Program to Showcase TOTAL30, Other Innovations that Meet Critical Patient and Practice Needs

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will showcase leading innovations and clinical research findings at the American Academy of Optometry Annual Meeting (#Academy21) in Boston, Massachusetts, from November 3-6, 2021. The meeting will mark the official launch of TOTAL30®, the first-and-only monthly replacement Water Gradient contact lens that feels like nothing even on day 30,1 to the professional eye care community. Alcon's engaging on-site program will feature events and more than a dozen clinical presentations around their most important eye care products, including the portfolio of permanent water surface technology contact lenses, dry eye and ocular health drops, and forthcoming innovations.

"Year after year, Alcon has delivered significant innovations across our Vision Care portfolio that help eye care professionals (ECPs) connect unmet patient and practice needs with industry-transforming products," said Sean Clark, General Manager, U.S. Vision Care, Alcon. "We are thrilled to officially introduce TOTAL30 contact lenses to the optometry community at this year's Academy meeting as an important option for their reusable lens patients seeking a more comfortable wearing experience. Our program is jam-packed with events centered around TOTAL30 and other important innovations that demonstrate our commitment to helping people see brilliantly."

TOTAL30 Contact Lenses to Officially Debut with Scientific Presentations, Immersive ECP Evening Event and Lens Try-On
In August, Alcon launched TOTAL30 monthly replacement contact lenses, which are clinically shown to feel like nothing, even at day 30.1 The lens science was born from the Water Gradient technology of DAILIES TOTAL1®. The following events will give meeting attendees hands-on experiences with the design and science of the lens throughout the meeting:

Additionally, there will be several data presentations taking place on Thursday, November 4, 2021, on the efficacy and clinical performance of TOTAL30, including:

Clinical and Survey Data Affirms Efficacy of PRECISION1 Water Surface Technology
Several clinical studies will be presented on November 4, 2021, highlighting PRECISION1® and PRECISION1 for Astigmatism, Alcon's one-day contact lenses, made with permanent water surface technology that keeps moisture on the lens surface for patient comfort.2 Data highlights include:

New Clinical Findings Affirm Efficacy of Products in Alcon's Dry Eye and Ocular Health Portfolio
Alcon's dry eye and ocular health portfolio features over-the-counter solutions and in-office devices, such as Systane® iLux®, Pataday® Once Daily Relief Extra Strength, and a variety of other brands, which support ocular surface health, dry eye, eye allergy itch symptom relief and more. Data highlights being presented at #Academy21 include:

Portfolio Expansions Will Deliver Industry Innovations for Unmet Patient, Practice Needs
In addition to the highlighted products and science noted above, Alcon is expanding its portfolio in 2022 with exciting new products, including:

In addition, Alcon recently acquired exclusive U.S. commercialization rights to Simbrinza® (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, a fixed combination indicated in the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Visit Alcon booth #813 for important information on Alcon's innovative products featured in this release.

Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. Our more than 23,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

^ Trademarks are the property of their respective owners.


  1. In a clinical study wherein patients (n=66) used CLEAR CARE® solution for nightly cleaning, disinfecting, and storing; Alcon data on file, 2021.
  2. Cummings S, Giedd B, Pearson C. Clinical performance of a new daily disposable spherical contact lens. Optom Vis Sci. 2019;96: E Abstract 195375.
  3. Silverstein S, Yeu E, Tauber J, et al. Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial. Clin Ophthalmol. 2020; 14:3167-3177.

Connect with us on

News published on 1 november 2021 at 14:35 and distributed by: